Spots Global Cancer Trial Database for Expanded Access for Pembrolizumab (MK-3475)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Expanded Access for Pembrolizumab (MK-3475)

Official Title: Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue.

Study ID: NCT03311542

Conditions

Melanoma (Skin)

Melanoma Recurrent

Glioblastoma Multiforme

Glioblastoma by Gene Expression Profile

Glioma of Brain

Interventions

pembrolizumab

Study Description

Brief Summary: This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

Detailed Description: Pembrolizumab has been approved by the U.S. Food and Drug Administration for the treatment of patients with Glioblastoma and Melanoma The Expanded Access Program (EAP) for this medicine in the U.S. is closed. The EAP will continue outside the U.S.